News

Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem

Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem

TORONTO, May 12, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in…

Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus

Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) — MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both…